1. Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical Study Group of Osaka University, Hepato‐Biliary‐Pancreatic Group
   Shogo Kobayashi et al, 2024, Hepatology Research CrossRef
2. Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
   Shizheng Mi et al, 2022, Scandinavian Journal of Gastroenterology CrossRef
3. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma
   Hiroshi Wada et al, 2016, Surgery CrossRef
4. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
   Thomas U Marron et al, 2022, The Lancet Gastroenterology & Hepatology CrossRef
5. Current and future treatments for hepatocellular carcinoma
   Alexander Schlachterman, 2015, World Journal of Gastroenterology CrossRef
6. Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization
   L. Zhu et al, 2018, Clinical and Translational Oncology CrossRef
7. Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment
   Haiping Zhang et al, 2019, The British Journal of Radiology CrossRef
8. Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis
   Kai Siang Chan et al, 2023, Acta Chirurgica Belgica CrossRef
9. Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection
   Daisaku Yamada et al, 2012, Annals of Surgical Oncology CrossRef